At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 147 enrolled
Drug / intervention
Surzebiclimab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors
In Brief
A Phase 2 clinical trial evaluating Surzebiclimab, Tislelizumab, and 1 other intervention for Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in and 2 related conditions. Completed, enrolled 147 participants across 40 sites in 6 countries.
Detailed Summary
This was an open-label, multicenter, nonrandomized Phase 1 and 2 clinical trial evaluating various combinations of surzebiclimab (BGB-A425) and/or alcestobart (LBL-007) with tislelizumab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLocally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion, NSCLC for Phase 2 Dose Expansion
CountriesAustralia, France, Italy, South Korea, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartNov 2018
First PostedNov 2018
Primary CompletionFeb 2025
TodayJul 2026
First PostedNov 16, 2018
Enrollment StartNov 13, 2018
Primary CompletionFeb 6, 2025
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 7.6 years ago
Interventions
Surzebiclimabdrug
Humanized immunoglobulin G1 (IgG1)-variant monoclonal antibody against TIM-3
Tislelizumabdrug
Humanized, IgG4-variant monoclonal antibody against PD-1
Alcestobartdrug
Human anti LAG-3 antibody